{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000102","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.991355+00:00","generated_at":"2026-06-01T06:21:02.911656+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Xeris stockholders approve all proposals; ESPP shares increased by 6.64M","bullets":["Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).","Ernst & Young ratified as auditor for FY2024 (99.5M for).","Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.","ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.","Broker non-votes on director election and advisory items: ~36.2M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000102","json":"https://secwatch.observer/filing/0001867096-24-000102.json","markdown":"https://secwatch.observer/filing/0001867096-24-000102.md","text":"https://secwatch.observer/filing/0001867096-24-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/0001867096-24-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/xers-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:21:02.911656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}